The NLRP3 inflammasome in osteoarthritis: a systematic review of traditional, complementary, and integrative medicine efficacy and underlying mechanisms.

Osteoarthritis is a painful joint condition that causes cartilage breakdown, inflammation, and chronic pain, primarily in the knees. Current treatment options are limited and often come with unwanted side effects. Researchers conducted a systematic review to investigate whether traditional, complementary, and integrative medicine (TCIM) approaches—including medicinal herbs, acupuncture, and other natural therapies—could help reduce osteoarthritis pain by targeting a specific inflammatory pathway called the NLRP3 inflammasome, which plays a key role in the body's immune response and contributes to joint inflammation.

The research team searched multiple medical databases for studies published between January 2000 and August 2024, ultimately analyzing 22 animal studies that met their criteria. The results were promising: TCIM interventions consistently reduced markers of inflammation, including NLRP3, IL-1β, IL-18, and Caspase-1, when compared to untreated osteoarthritis controls. The effects were moderate to large across all measurements, and results remained consistent regardless of the type of osteoarthritis model used, the specific TCIM intervention applied, or the animal species studied.

What this means for patients: These findings suggest that traditional medicine approaches like acupuncture and herbal treatments may help manage osteoarthritis pain by reducing inflammation at a molecular level. While these results are encouraging, it's important to note that all studies were conducted in animals, not humans. More clinical research is needed to confirm whether these benefits translate to people with osteoarthritis. If you're considering acupuncture or other complementary therapies for osteoarthritis, consult with a licensed acupuncturist or qualified healthcare provider experienced in treating joint conditions.

This systematic review and meta-analysis examined TCIM interventions targeting the NLRP3 inflammasome pathway in osteoarthritis management. Twenty-two in vivo studies (21 in meta-analysis) published from January 2000 to August 2024 were identified through comprehensive database searches. TCIM interventions, including medicinal herbs and acupuncture, demonstrated consistent reduction in NLRP3, IL-1β, IL-18, and Caspase-1 expression compared to OA controls. Pooled effects showed moderate-to-large effect sizes across all molecular markers with remarkably low between-study heterogeneity (I² ≈ 0%). Subgroup analyses by OA induction model, intervention type, and species indicated consistent directional effects. Clinical takeaway: Preclinical evidence strongly supports TCIM modulation of NLRP3 inflammasome-mediated inflammation in OA. These mechanistic insights provide a rational basis for TCIM use in OA-related pain management, though clinical translation studies are urgently needed to establish efficacy, optimal dosing, and safety profiles in human populations before routine clinical implementation.